<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report JUNE 26, 1995
---------------
SEQUUS PHARMACEUTICALS, INC.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-15847 94-3031934
- --------------------------------------------------------------------------------
(State or Other (Commission (I.R.S. Employer
Jurisdiction of File Number) Identification No.)
Incorporation)
960 HAMILTON COURT
MENLO PARK, CALIFORNIA 94025
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (415) 323-9011
--------------
LIPOSOME TECHNOLOGY, INC.
- --------------------------------------------------------------------------------
(Former Name, if Changed Since Last Report)
AN EXHIBIT INDEX IS ON PAGE 4 OF THIS REPORT
PAGE 1
<PAGE>
Item 5. OTHER EVENTS
On June 26, 1995, Liposome Technology, Inc. officially changed its
name to SEQUUS Pharmaceuticals, Inc. ("SEQUUS"). A copy of SEQUUS'
press release dated June 26, 1995 is attached hereto as Exhibit
99.1 and the information contained therein is incorporated by
reference herein in its entirety.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) The following exhibits are filed as part of this Report:
3.1 Registrant's Restated Certificate of Incorporation. (1)
3.1.1 Certificate of Ownership and Merger of SEQUUS
Pharmaceuticals, Inc. into Liposome Technology, Inc. (1)
99.1 Press Release of SEQUUS dated June 26, 1995.
- -----------------------------------
(1) Incorporated herein by reference from the Registrant's Registration
Statement on Form S-3 filed on June 26, 1995.
PAGE 2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SEQUUS PHARMACEUTICALS, INC.
Registrant
Date: June 26, 1995 By: /s/ Sally A. Davenport
-------------------- ------------------------------
Secretary
PAGE 4
<PAGE>
EXHIBIT INDEX
Exhibit
- -------
3.1 Registrant's Restated Certificate of Incorporation. (1)
3.1.1 Certificate of Ownership and Merger of SEQUUS Pharmaceuticals, Inc.
into Liposome Technology, Inc. (1)
99.1 Press Release of SEQUUS dated June 26, 1995.
- --------------------------------------
(1) Incorporated herein by reference from the Registrant's Registration
Statement on Form S-3 filed on June 26, 1995.
PAGE 4
<PAGE>
Exhibit 99.1
CONTACT: SEQUUS PHARMACEUTICALS, INC. BURNS MCCLELLAN
Joseph M. Limber Lilian Stern (Investor Inquiries)
Executive VP and Acting COO 212-505-1919
Donald J. Stewart Justin Jackson (Media Inquiries)
VP Finance 415-399-4525
4l5/323-90ll
FOR IMMEDIATE RELEASE
LIPOSOME TECHNOLOGY CHANGES NAME TO SEQUUS PHARMACEUTICALS
--SEQUUS Pharmaceuticals will trade under new Nasdaq symbol "SEQU"--
MENLO PARK, CA, June 26, 1995 -- Liposome Technology, Inc. (Nasdaq: LTIZ) today
announced that it has changed its name to SEQUUS Pharmaceuticals, Inc.
"The name change is part of an overall strategy to create a pharmaceutical
identity for the Company and its products", said Chairman and Chief Executive
Officer Nick V. Arvanitidis, Ph.D. "We are approaching a major milestone with
the anticipated US launch of DOXIL-Registered Trademark-to treat AIDS patients
with refractory Kaposi's sarcoma. This is a period of significant change for
the Company and, thus, the time is right to adopt a new name which reflects our
transition to a pharmaceutical company."
DOXIL is SEQUUS' proprietary long-circulating STEALTH-Registered Trademark-
liposome formulation of the widely prescribed anticancer drug doxorubicin
hydrochloride. On February 14, 1995, DOXIL was recommended for approval for
treatment of refractory AIDS-KS by the FDA's Oncologic Drugs Advisory Committee
under the FDA's accelerated approval procedures. The Company is currently
working with the FDA to finalize the design of a Phase IV "post-marketing"
study, the product labeling, and the promotional and advertising materials, as
required for final approval by the FDA.
Founded in 1981 and headquartered in Menlo Park, California (with offices in
London, England), SEQUUS Pharmaceuticals is engaged in the development,
manufacture, marketing and sale of proprietary pharmaceutical products for the
critical care market. The Company is developing DOXIL to treat advanced forms
of cancer, including AIDS-related Kaposi's sarcoma. In addition, the Company is
focusing on the clinical development and commercialization of its proprietary
antifungal product AMPHOCIL-TM-. AMPHOCIL is approved in the United Kingdom,
Finland, and the Republic of Ireland. SEQUUS Pharmaceuticals has been publicly
traded on the Nasdaq Stock Market's National Market System since 1987.
PAGE 5
